InMode (NASDAQ:INMD) Issues FY20 Earnings Guidance

Share on StockTwits

InMode (NASDAQ:INMD) issued an update on its FY20 earnings guidance on Tuesday morning. The company provided EPS guidance of $1.85-1.93 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.70. The company issued revenue guidance of $190-198 million, compared to the consensus revenue estimate of $191.21 million.InMode also updated its FY 2020
Pre-Market guidance to 1.85-1.93 EPS.

INMD traded down $1.21 during midday trading on Wednesday, reaching $39.48. 1,589,225 shares of the company’s stock were exchanged, compared to its average volume of 1,371,724. The company has a quick ratio of 7.47, a current ratio of 7.83 and a debt-to-equity ratio of 0.01. InMode has a one year low of $13.06 and a one year high of $58.76. The company’s 50-day moving average is $43.27.

InMode (NASDAQ:INMD) last announced its quarterly earnings results on Tuesday, February 18th. The healthcare company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.07. The firm had revenue of $47.00 million during the quarter, compared to analysts’ expectations of $42.48 million. InMode had a net margin of 30.33% and a return on equity of 50.50%. The company’s revenue for the quarter was up 63.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.22 earnings per share. Equities research analysts expect that InMode will post 1.55 EPS for the current fiscal year.

A number of research analysts have commented on INMD shares. Canaccord Genuity restated a buy rating and set a $50.00 price target on shares of InMode in a research note on Wednesday. Barclays restated an overweight rating and set a $48.00 price objective (up from $45.00) on shares of InMode in a research note on Wednesday. Robert W. Baird restated an outperform rating and set a $55.00 price objective (up from $45.00) on shares of InMode in a research note on Tuesday, January 28th. Finally, Zacks Investment Research lowered shares of InMode from a strong-buy rating to a hold rating in a research note on Wednesday, January 8th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $45.20.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments.

Featured Story: What does a market perform rating mean?

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with's FREE daily email newsletter.